awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Table
SPARQL
Graphs
1
1
Services
1
1
Assets
0
0
Insights
Schema
BETA
Class frequency
Class hierarchy
Q43492386-764E8F7A-FDC8-433C-BAFC-1CA395C87836
Q43492386-764E8F7A-FDC8-433C-BAFC-1CA395C87836
BestRank
Statement
http://www.wikidata.org/entity/statement/Q43492386-764E8F7A-FDC8-433C-BAFC-1CA395C87836
De novo AML patients with favourable-intermediate karyotype may benefit from the addition of low-dose gemtuzumab ozogamicin (GO) to fludarabine, Ara-C and idarubicin (FLAI): a contribution to the reopened "GO question".
P2860
Q43492386-764E8F7A-FDC8-433C-BAFC-1CA395C87836
BestRank
Statement
http://www.wikidata.org/entity/statement/Q43492386-764E8F7A-FDC8-433C-BAFC-1CA395C87836
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
193c5fc80baf802731ef601af9bf82a55c2b3793
P2860
Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study.